Fig. 1From: Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trialKaplan-Meier survival probability without grade 2 or more ALT elevation according to the use of tipranavir (TPV) in baseline regimen (BR)Back to article page